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Abstract 
 
An 18-year-old Malay gentleman was noted to have profound bilateral blurred vision for one month duration, 
associated with loss of weight, appetite, low grade fever and abdominal distension. Visual acuity on presentation was 
6/60 on the right, counting finger on the left with no afferent pupillary defect. Anterior segments were unremarkable. 
Vitreous cells were occasional bilaterally. Fundus revealed multiple choroidal and sub-retinal Roth spots with areas 
of pre-retinal and intra-retinal haemorrhages, involving the macula in the left eye. Vessels were dilated and tortuous 
in all quadrants of the right eye. Many areas of capillary fall out at peripheral retina were demonstrated in fundus 
fluorescein angiogram.  Further systemic and laboratory review confirmed the diagnosis of CML and chemotherapy 
was initiated. Both eye ischaemic retinopathy secondary to CML was confirmed and scatter pan retinal 
photocoagulation was performed bilaterally. Good improvement in vision noted during subsequent follow up to 6/24 
on the right, 6/60 on the left. High levels of suspicion and accurate early recognition of fundus changes are vital in 
these types of cases to ensure the institution of prompt treatment. 
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Introduction 
 
Leukaemia is characterised by neoplastic proliferation 
of white bloodcells which is categorized into 
myelogenous and lymphocytic origins, and are further 
subdivided based on acute or chronic phases. CML, 
(chronic myeloid leukemia, also known as  chronic 
myelocytic leukemia) accounts for 15% to 20% of adult  
leukemias. It is associated with a BCR-ABL fusion 
gene, better known as the Philadelphia Chromosome 
that is seen in mostly 95% of patients, which encodes 
for an active protein thyrosine kinase. This protein is the 
important site of action of designed drugs for this 
disease (1). We report a case of chronic myeloid 
leukaemia with ocular manifestations as the initial 
presentation, requiring prompt and accurate diagnosis in 
tackling the underlying cause in such cases. 
Case Report 
 
An 18-year-old Malay gentleman presented with 
bilateral profound blurred vision for duration of a month. 
Further history taking gathered associated symptoms of 
loss of appetite and weight with episodes of low grade 
fever and abdominal distension within the same time 
frame for which, he did not seek medical treatment, as it 
was not as significant as the visual disturbance. Visual 
acuity at presentation was 6/60 on the right and counting 
finger on the left. No afferent pupillary defect noted. 
Anterior segments were unremarkable. Occasional 
vitreous cells were seen bilaterally. Both fundi revealed 
pink optic discs with a cup to disc ratio of 0.3. Multiple 
choroidal and subretinalroth spots distributed throughout 
all the quadrants with numerous pre and intra retinal 
haemorrhages involving the left macula. Vessels on the
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Figure 1: Fundus photographs showing multiple haemorrhages bilaterally (white arrows), with right venous tortuosity (black 
arrows) and left macula involvement (yellow arrows).  
 
 
 
Figure 2:  Fundus photographs showing resolved haemorrhages bilaterally with less venous tortuosity 
 
right fundus were exceptionally dilated and tortuous 
(Fig 1). 
 
Urgent fundus fluorescein angiogram (FFA) revealed 
multiple numerous areas of capillary fall out (CFO) at 
the peripheries, however with a normal filling time. 
Systemic review showed evidence of 
hepatosplenomegaly despite him appearing clinically 
well. Further haematological profile showed 
hyperleukocytosis, to 570 x 109/l .Bone marrow 
aspiration cytology and trephine biopsy brought about 
the diagnosis of chronic myeloid leukaemia (CML) in 
chronic phase, substantiated with abnormal 
Fluorescence in situ hybridization (FISH) result, 
positive for BCR/ABL translocation.  Magnetic 
resonance imaging (MRI) brain and orbit did not 
produce any evidence of Leukemic infiltrations .He 
was subjected to multiple sittings of leukopharesis and 
was commenced with intravenous Cytarabine 150 mg 
daily initially and later oral Imatinib 200 mg daily, 
subsequently changed to Nilotinib 300 mg twice daily. 
A diagnosis of bilateral ischaemic retinopathy 
secondary to CML was established and we proceeded 
with bilateral scatter pan retinal photocoagulation. 
Subsequent follow up visit showed significant 
improvement in vision to 6/24 on the right and 6/60 on 
the left. There was a marked reduction of 
haemorrhagic areas and infiltrates in both fundi (Fig. 
2). Repeat FFA demonstrated reduction in the CFO 
areas with a better perfusion of retinal vasculature. 
 
Discussion 
 
Many underlying systemic pathologies, commonly 
diabetes mellitus, hypertension, anaemias and 
leukaemia may present with bilateral retinal 
haemorrhages. In this case, a laboratory analysis of 
blood counts with differentials and cytological 
analyses were mandatory in confirmation of CML and 
hence the leukemic retinopathy. CML can remain 
asymptomatic in up to 50% of cases (2). Leukemic 
ocular involvement can be seen in any structure within 
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the eye. Retinal and choroidal involvement are 
commonly seen during the course of the illness, 
reported in up to 50 to 90% of cases, usually rare as 
the presenting symptoms, however demonstrated that 
it may not always be true as in this case. Roth spots 
(which refers to haemorrhages with white centers 
containing platelet fibrin deposits or leukemic 
infiltrates), retinal neovascularization and retinal 
venous tortuosity or obstruction are some of the 
features frequently seen in leukemic retinopathies (3). 
Ocular manifestations of CML patients are not to be 
taken lightly as they demonstrate a lower 5-year 
survival compared with those without (4). Chronic 
phase CML is best treated with tyrosine kinase 
inhibitors (TKIs) namely Imatinib which is the first 
line of treatment currently, which is recommended to 
be maintained for long duration to avoid relapse of the 
disease (5). Nilotinib however is noted to be more 
potent and effective in producing molecular and 
cytogenic response in newly diagnosed chronic phase 
CML (6). Others include interferon alpha, cytotoxic 
agents such as hydroxyurea, lastly allogeneic 
hematopoietic cell transplantation. Recent study 
indicate that tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) has the CML cells 
apoptosis- inducing- property. It is also noted that 
dasatinib and TRAIL combination has brought about 
good therapeutic effect. Underlying retinopathy 
usually shows resolution with the treatment of CML 
(8). 
 
Conclusion  
 
Leukemic retinopathies usually show a good recovery 
when the underlying cause is well recognised and 
treated early. High levels of suspicion and accurate 
early recognition of fundus changes are vital in these 
types of cases to ensure the institution of prompt 
treatment to secure good visual potentials. Immediate 
initiation of oral tyrosine kinase inhibitors (TKIs) such 
as Imatininib and Nilotinib and local ocular laser 
theraphy to minimise the local ocular ischemia has 
brought about good clinical response in this case. Any 
delay in the initiation of the laser theraphy would have 
compromised his vision and lead to irreversible visual 
loss. 
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